CONSIDER KEYTRUDA® FOR YOUR PATIENTS WITH MELANOMA IN YOUR PRACTICE

KEYTRUDA® is indicated for:

- Treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
- Adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.
- Adjuvant treatment of adult patients with Stage III melanoma with lymph node involvement who have undergone complete resection.

Do you have a patient like:



James*

who has Stage IIB melanoma?

Kristina*

who has Stage IIC melanoma?

Lim*

who has Stage III melanoma?

Pranav*

who has metastatic melanoma?

Jun*

who has Stage IV melanoma?

MERCK

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

BRAF=v-Raf murine sarcoma viral oncogene homolog B1; MEK=mitogen-activated protein kinase kinase.

* Fictitious patient. May not be representative of all patients.

DO YOU HAVE A PATIENT LIKE JAMES* WITH STAGE IIB MELANOMA?

James*

61 years old

- Archeologist

Clinical presentation +

* Fictitious patient. May not be representative of all patients.

JAMES'S* CLINICAL PRESENTATION

1 INITIAL PRESENTATION & DIAGNOSIS

- Patient visited his family doctor as he noticed a large, rapidly growing plaque on his shoulder blade
- Diagnosed with asthma managed with inhaled therapy
- Diagnosis of melanoma confirmed with biopsy
- Computed tomography (CT) revealed no lymph nodes involvement

2 TREATMENT

- 2 surgeries were performed: the first one local by plastic surgery and the second one wider under general anesthesia
- Split-thickness skin graft was applied to cover the defect
- Successful graft and recovery

3 CLINICAL NOTES

- ECOG PS: 0
- N0 disease revealed with biopsy
- No evidence of rapidly progressive disease
- No brain metastases
- Stage IIB

Would you consider KEYTRUDA® for a patient like James*?

← Patient background

Take a look at the published KN-716 study +

ECOG PS=Eastern Cooperative Oncology Group performance status; N0=no cancer in nearby lymph nodes.

* Fictitious patient. May not be representative of all patients.

DO YOU HAVE A PATIENT LIKE KRISTINA*

WITH STAGE IIC MELANOMA?

Kristina*

70 years old

- Director at an investment firm
- Diagnosed with type 2 diabetes mellitus 4 years ago controlled on treatment for non-insulin dependent

Clinical presentation +

* Fictitious patient. May not be representative of all patients.

KRISTINA'S* CLINICAL PRESENTATION

1

INITIAL PRESENTATION & DIAGNOSIS

- Patient observed a slowly growing plantar lesion that she neglected to treat as associated to shoe rubbing
- Diagnosis of melanoma 6 months later, when referred to a dermatologist
- Paraffin sections stained with Haematoxylin – and Eosin and Masson's Fontana showed features of malignant melanoma
- Complete resection
- Mohs surgery performed by surgeon to remove epidermal lesion

2

CLINICAL NOTES

- ECOG PS: 0
- Normal baseline LDH
- Stage IIC

Would you consider KEYTRUDA® for a patient like Kristina*?

Patient background

Take a look at the published KN-716 study

ECOG PS=Eastern Cooperative Oncology Group performance status; LDH=lactate dehydrogenase.

* Fictitious patient. May not be representative of all patients.

DO YOU HAVE A PATIENT LIKE LIM*

WITH COMPLETELY RESECTED STAGE III MELANOMA WITH LYMPH NODE INVOLVEMENT?

Lim*

54 years old

- Retired, former landscaper
- Widowed with 3 children and 6 granddaughters
- Currently taking anxiolytics to manage her anxiety

Clinical presentation +

* Fictitious patient. May not be representative of all patients.

LIM'S* CLINICAL PRESENTATION

1 INITIAL PRESENTATION & DIAGNOSIS

- Patient noticed dark-brown ulcerated nodules on the palms that she confused with warts
- Diagnosed with melanoma 2 years after the appearance of the first lesion during a routine exam
- Extensive palmar lesions

2 TREATMENT

- Lymphadenectomy performed

3 CLINICAL NOTES

- ECOG PS: 0
- Stage III melanoma
- PD-L1 positive
- BRAF V600E detected

Would you consider KEYTRUDA® for a patient like Lim*?

Patient background

Take a look at the published KN-054 study

BRAF=v-Raf murine sarcoma viral oncogene homolog B1;
ECOG PS=Eastern Cooperative Oncology Group performance status; PD-L1=programmed death-ligand 1.

* Fictitious patient. May not be representative of all patients.

DO YOU HAVE A PATIENT LIKE PRANAV*

WHO HAS STAGE IV MELANOMA WITH METASTASES?

Pranav*

62 years old

- Former athlete and photographer
- Single
- Taking vitamins, proteins and collagen supplements

Clinical presentation +

* Fictitious patient. May not be representative of all patients.

PRANAV'S* CLINICAL PRESENTATION

1

INITIAL PRESENTATION & DIAGNOSIS

- Consulted his family doctor when his hairstylist noted his rapidly growing mole with irregular borders on his scalp
- Additional lesions were detected during a subsequent visit to his dermatologist
- Axillary lymph nodes detected with routine exam
- Computed tomography (CT) revealed metastases in the lungs and lymph nodes

2

CLINICAL NOTES

- ECOG PS: 1
- No BRAF mutation detected
- M stage: M1c
- Unresectable stage IV

Would you consider KEYTRUDA® for a patient like Pranav*?

← Patient background

Take a look at the published KN-006 study +

BRAF=v-Raf murine sarcoma viral oncogene homolog B1;
ECOG PS=Eastern Cooperative Oncology Group performance status; M stage=metastatic stage.

* Fictitious patient. May not be representative of all patients.

DO YOU HAVE A PATIENT LIKE JUN* WITH UNRESECTABLE METASTATIC MELANOMA?

Jun*

72 years old

- Retired physical education teacher
- Married, 4 children and 7 grandchildren
- Currently taking an antihypertensive and a statin

Clinical presentation +

* Fictitious patient. May not be representative of all patients.

JUN'S* CLINICAL PRESENTATION

1

CLINICAL NOTES

- BRAF status: V600E mutation confirmed
- ECOG PS: 1
- M stage: M1c
- Previous melanoma treatment included ipilimumab and a BRAF inhibitor

Would you consider KEYTRUDA® for a patient like Jun*?

Patient background

Take a look at the published KN-002 study

BRAF=v-Raf murine sarcoma viral oncogene homolog B1;
ECOG PS=Eastern Cooperative Oncology Group performance status; M stage=metastatic stage.

* Fictitious patient. May not be representative of all patients.

IMPORTANT SAFETY INFORMATION

Clinical use:

Pediatrics: KEYTRUDA® as monotherapy is indicated for the treatment of pediatric patients 12 years and older with Stage IIB or IIC melanoma who have undergone complete resection.

The safety and efficacy of KEYTRUDA® has not been established for pediatric patients with conditions other than melanoma (Stage IIB or IIC).

Relevant warnings and precautions:

- Immune-mediated adverse reactions, including severe and fatal cases:
  - Pneumonitis
  - Colitis
  - Hepatitis
  - Nephritis and renal dysfunction
  - Endocrinopathies including adrenal insufficiency, hypophysitis, type 1 diabetes mellitus and thyroid disorders
  - Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis
- Other immune-mediated adverse events including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis, vasculitis, Guillain-Barré syndrome, hemolytic anemia, pancreatitis, myelitis, hypoparathyroidism, myocarditis, sclerosing cholangitis
- Solid organ transplant rejection
- Allogeneic stem cell transplant after and before treatment
- Severe infusion-related reactions
- Teratogenic toxicity
- Women should avoid pregnancy and breastfeeding during treatment and for at least 4 months after it
- Patients with hepatic impairment
- Renal impairment
- Driving and operating machinery
- Monitoring requirements
- Pediatrics
- Geriatrics

For more information:

Please consult the Product Monograph at www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf for important information regarding adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The Product Monograph is also available by calling us at 1-800-567-2594 or by email at medinfocanada@merck.com.

Reference: KEYTRUDA® Product Monograph. Merck Canada Inc. December 29, 2022.

MERCK

CA-OOC-00029

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

Merck Canada Inc.
16750 Trans-Canada Highway,
Kirkland (Quebec), Canada, H9H 4M7